Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transplant Ineligible”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05272826
What this trial is testing

Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

Who this might be right for
Multiple Myeloma
Canadian Myeloma Research Group 75
Early research (Phase 1)Looking for participantsNCT07477587
What this trial is testing

Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma (MM)
Shanghai Henlius Biotech 258
Large-scale testing (Phase 3)Ended earlyNCT02145598
What this trial is testing

Treatment Optimization in Patients With Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dr. med. Lars-Olof Muegge 85
Not applicableNot Yet RecruitingNCT07532473
What this trial is testing

REal World MAIA UK OutcomEs

Who this might be right for
Myeloma
The Royal Wolverhampton Hospitals NHS Trust 300
Testing effectiveness (Phase 2)Looking for participantsNCT07072494
What this trial is testing

CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study

Who this might be right for
Acute Lymphoblastic Leukemia
Zhujiang Hospital 30
Testing effectiveness (Phase 2)Study completedNCT02237261
What this trial is testing

Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma

Who this might be right for
Multiple Myeloma
University Hospital Heidelberg 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07601100
What this trial is testing

Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

Who this might be right for
Newly Diagnosed Multiple Myeloma
Dana-Farber Cancer Institute 88
Early research (Phase 1)Ended earlyNCT03015792
What this trial is testing

Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Mayo Clinic 18
Early research (Phase 1)UnknownNCT04886206
What this trial is testing

Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Myeloid Leukemia (AML)
Nantes University Hospital 12
Large-scale testing (Phase 3)Study completedNCT01818752
What this trial is testing

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 955
Not applicableStudy completedNCT03602755
What this trial is testing

The First-line Treatment of Patients With Newly Diagnosed Transplant-ineligible Multiple Myeloma in Spain

Who this might be right for
Multiple Myeloma
Celgene 706
Testing effectiveness (Phase 2)Study completedNCT04022005
What this trial is testing

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Sun Yat-sen University 54
Testing effectiveness (Phase 2)UnknownNCT05280275
What this trial is testing

Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Who this might be right for
Multiple MyelomaNeoplasmsNeoplasms, Plasma Cell+5 more
Hellenic Society of Hematology 36
Large-scale testing (Phase 3)Active Not RecruitingNCT02390869
What this trial is testing

Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Who this might be right for
Lymphoma, Follicular
Fondazione Italiana Linfomi - ETS 128
Not applicableStudy completedNCT02537808
What this trial is testing

Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
iOMEDICO AG 172
Testing effectiveness (Phase 2)Looking for participantsNCT04627753
What this trial is testing

Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Who this might be right for
Primary CNS Lymphoma
Kim, Seok Jin 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06646666
What this trial is testing

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Who this might be right for
B-cell Non Hodgkin Lymphoma
Ruijin Hospital 35
Testing effectiveness (Phase 2)Study completedNCT02072863
What this trial is testing

Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Amgen 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT05860036
What this trial is testing

VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 40
Testing effectiveness (Phase 2)Study completedNCT02624492
What this trial is testing

To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Boehringer Ingelheim 21
Next Page